Literature DB >> 2874227

Synthesis and beta-adrenergic receptor blocking potency of 1-(substituted amino)-3-(4-indolyloxy)propan-2-ols.

S M Tejani-Butt, D J Brunswick.   

Abstract

Although (-)-[125I]iodopindolol (IPIN) can be used to label beta-adrenergic receptors in the central nervous system in vivo, use of this ligand for receptor imaging studies in humans may be limited due to its relatively poor penetration into the brain. As a first step toward the development of radioligands for imaging studies, we report the synthesis and measurement of in vitro binding affinity to beta-receptors of a series of 1-(substituted amino)-3-(4-indolyloxy)-propan-2-ol derivatives. The synthesized compounds vary widely in their lipophilicity as measured by their distribution coefficients between phosphate buffer and octanol at pH 7.4. The affinity of these compounds for beta-receptors, as measured by their inhibition of binding of IPIN to rat cortical and cerebellar membranes in vitro, ranges from 2- to 100-fold less potent than pindolol; the most potent compounds have Ki values of 2-5 nM. The radiolabeled analogues of some of these compounds may prove useful for receptor imaging studies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874227     DOI: 10.1021/jm00158a035

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Evaluation of mono- and dibenzoyl esters of dopamine as potential pro-drugs for dopamine in the central nervous system.

Authors:  S M Tejani-Butt; M Hauptmann; A D'Mello; A Frazer; J M Marcoccia; D J Brunswick
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-11       Impact factor: 3.000

2.  Structure-Activity Relationship and Biological Investigation of SR18292 (16), a Suppressor of Glucagon-Induced Glucose Production.

Authors:  Hua Lin; Kfir Sharabi; Li Lin; Claudia Ruiz; Di Zhu; Michael D Cameron; Scott J Novick; Patrick R Griffin; Pere Puigserver; Theodore M Kamenecka
Journal:  J Med Chem       Date:  2021-01-12       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.